About Opexa Therapeutics
Opexa Therapeutics is a company based in The Woodlands (United States) founded in 2004 was acquired by Acer Therapeutics in July 2017.. Opexa Therapeutics has raised $5.84 million across 3 funding rounds from investors including Acer Therapeutics. The company has 9 employees as of December 31, 2016. Opexa Therapeutics offers products and services including Tcelna and OPX-212. Opexa Therapeutics operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter The Woodlands, United States
- Employees 9 as on 31 Dec, 2016
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Opexa Therapeutics, Inc.
-
Annual Revenue
$2.91 M14as on Dec 31, 2016
-
Net Profit
$-7.98 M34as on Dec 31, 2016
-
EBITDA
$-7.75 M34as on Dec 31, 2016
-
Total Equity Funding
$5.84 M (USD)
in 3 rounds
-
Latest Funding Round
$650 K (USD), Series A
Feb 15, 2013
- Investors
-
Employee Count
9
as on Dec 31, 2016
-
Acquired by
Acer Therapeutics
(Jul 03, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Opexa Therapeutics
Opexa Therapeutics offers a comprehensive portfolio of products and services, including Tcelna and OPX-212. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Personalized T-cell therapy for multiple sclerosis treatment
Autologous T-cell therapy for neuromyelitis optica
Funding Insights of Opexa Therapeutics
Opexa Therapeutics has successfully raised a total of $5.84M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $650 thousand completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $650,000
-
First Round
First Round
(25 Apr 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2013 | Amount | Series A - Opexa Therapeutics | Valuation |
investors |
|
| Jul, 2012 | Amount | Series A - Opexa Therapeutics | Valuation |
investors |
|
| Apr, 2009 | Amount | Seed - Opexa Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Opexa Therapeutics
Opexa Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Acer Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Treatments for ultra-rare diseases like vEDS and MSUD are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Opexa Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Opexa Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Opexa Therapeutics Comparisons
Competitors of Opexa Therapeutics
Opexa Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, Poseida Therapeutics and Juno Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Opexa Therapeutics
Frequently Asked Questions about Opexa Therapeutics
When was Opexa Therapeutics founded?
Opexa Therapeutics was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Where is Opexa Therapeutics located?
Opexa Therapeutics is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Is Opexa Therapeutics a funded company?
Opexa Therapeutics is a funded company, having raised a total of $5.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.1M, raised on Apr 25, 2009.
How many employees does Opexa Therapeutics have?
As of Dec 31, 2016, the latest employee count at Opexa Therapeutics is 9.
What is the annual revenue of Opexa Therapeutics?
Annual revenue of Opexa Therapeutics is $2.91M as on Dec 31, 2016.
What does Opexa Therapeutics do?
Opexa Therapeutics was established in 2004 through the merger of PharmaFrontiers and Opexa Pharmaceuticals. Patient-specific immunotherapies are developed by the company for multiple sclerosis treatment within the biotechnology sector. The leading candidate, Tcelna, is designed for Secondary Progressive Multiple Sclerosis. Operations are conducted from The Woodlands, United States, focusing on autoimmune disease applications.
Who are the top competitors of Opexa Therapeutics?
Opexa Therapeutics's top competitors include ADMA Biologics, Juno Therapeutics and Lyell Immunopharma.
What products or services does Opexa Therapeutics offer?
Opexa Therapeutics offers Tcelna and OPX-212.
Who are Opexa Therapeutics's investors?
Opexa Therapeutics has 1 investor. Key investors include Acer Therapeutics.